Iron and hepatitis C: beginning to make sense.
Bassett
Mark L
ML
D000428:Alcohol Drinking / Q000009:adverse effects; D000998:Antiviral Agents / Q000627:therapeutic use*; D018450:Disease Progression; D024921:Drug Resistance, Multiple, Viral; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007501:Iron / Q000378:metabolism*; D019190:Iron Overload / Q000378:metabolism / Q000473:pathology / Q000628:therapy / Q000821:virology*; D008099:Liver / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D018962:Phlebotomy; D010976:Platelet Count; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D012307:Risk Factors; D012720:Severity of Illness Index; D012737:Sex Factors; D000637:Transaminases / Q000097:blood; D017211:Treatment Failure; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D007501:Iron; D000637:Transaminases